Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia

References

• van den Ancker W, Terwijn M, Westers TM, et al. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia. 2010;24(7):1392–1396. doi:10.1038/leu.2010.119
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Qasrawi A, Gomes V, Chacko CA, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leukemia Res. 2020;89:106301. doi:10.1016/j.leukres.2020.106301
   PubMed Web of Science ®Google Scholar
• Huang J, Zhou J, Xiao M, et al. The association of complex genetic background with the prognosis of acute leukemia with ambiguous lineage. Sci Rep. 2021;11(1):24290. doi:10.1038/s41598-021-03709-7
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. 2010;5(2):e9332. doi:10.1371/journal.pone.0009332
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8–13. doi:10.1002/ijc.23607
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA, Hou J, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284. doi:10.1200/JCO.18.01600
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.cd-16-0313
   PubMed Web of Science ®Google Scholar
• Heesch S, Neumann M, Schwartz S, et al. Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Ann Hematol. 2013;92(6):747–758. doi:10.1007/s00277-013-1694-4
   PubMed Web of Science ®Google Scholar
• Duong VH, Begna KH, Kashanian S, et al. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Ann Hematol. 2020;99(9):2119–2124. doi:10.1007/s00277-020-04179-z
   PubMed Web of Science ®Google Scholar
• Weinberg OK, Hasserjian RP, Baraban E, et al. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathol. 2019;32(9):1373–1385. doi:10.1038/s41379-019-0263-3
   PubMed Web of Science ®Google Scholar
• Gerr H, Zimmermann M, Schrappe M, et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol. 2010;149(1):84–92. doi:10.1111/j.1365-2141.2009.08058.x
   PubMed Web of Science ®Google Scholar
• Hrusak O, de Haas V, Stancikova J, et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018;132(3):264–276. doi:10.1182/blood-2017-12-821363
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Onciu M, Pounds S, et al. Acute mixed lineage leukemia in children: the experience of St Jude Children’s Research Hospital. Blood. 2009;113(21):5083–5089. doi:10.1182/blood-2008-10-187351
   PubMed Web of Science ®Google Scholar
• Liu QF, Fan ZP, Wu MQ, et al. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol. 2013;92(5):679–687. doi:10.1007/s00277-012-1662-4
   PubMed Web of Science ®Google Scholar
• Patel SH, Vasu S, Guo L, et al. Molecular complete remission following ivosidenib in a patient with an acute undifferentiated leukemia. J Natl Comprehen Cancer Network. 2020;18(1):6–10. doi:10.6004/jnccn.2019.7368
   PubMed Web of Science ®Google Scholar
•  Polishchuk V, Khazal S, Berulava G, et al. 55-Azacitidine monotherapy followed by related haploidentical hematopoietic stem cell transplantation achieves durable remission in a pediatric patient with acute undifferentiated leukemia refractory to high-dose chemotherapy. Pediatr Blood Cancer. 2016;63(6):1111–1112. doi:10.1002/pbc.25948.
   PubMed Web of Science ®Google Scholar
• Liu K, Li Y, Qiu S, et al. Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified. Exp Hematol Oncol. 2021;10(1):46. doi:10.1186/s40164-021-00239-w
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Toya T, Kishida Y, et al. Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2018;59(12):3006–3009. doi:10.1080/10428194.2018.1441410
   PubMed Web of Science ®Google Scholar
• Chen X, Glytsou C, Zhou H, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9(7):890–909. doi:10.1158/2159-8290.CD-19-0117
   PubMed Web of Science ®Google Scholar
• Pollyea Stevens DA, Jones BM, Winters CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866. doi:10.1038/s41591-018-0233-1
   PubMed Web of Science ®Google Scholar
• Lee JB, Khan DH, Hurren R, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138(3):234–245. doi:10.1182/blood.2020009081
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X
   PubMed Web of Science ®Google Scholar
• Kadia TM, Kantarjian H, Kornblau S, et al. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012;118(22):5550–5559. doi:10.1002/cncr.27596
   PubMed Web of Science ®Google Scholar
• Desikan SP, Ravandi F, Pemmaraju N, et al. A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations. Acta Haematol. 2022;145(5):529–536. doi:10.1159/000525566
   PubMed Web of Science ®Google Scholar
• Park J, Park H, Byun JM, et al. Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncol Lett. 2021;22(5):745. doi:10.3892/ol.2021.13006
   PubMed Web of Science ®Google Scholar
• Liu X, Ye Q, Zhao XP, et al. RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis. Clin Chim Acta. 2019;489:254–260. doi:10.1016/j.cca.2018.08.040
   PubMed Web of Science ®Google Scholar
• Manola KN. Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview. Br J Haematol. 2013;163(1):24–39. doi:10.1111/bjh.12484
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar